Differential Expression of MicroRNAs in Tissues and Plasma Co-exists as a Biomarker for Pancreatic CancerShadan Ali1, Hala Dubaybo2, Randall E Brand3 and Fazlul H Sarkar1,2*
- *Corresponding Author:
- Fazlul H. Sarkar
Department of Pathology, Karmanos Cancer Institute
Wayne State University School of Medicine
740 Hudson Webber Cancer Research Center
4100 John R Street, Detroit, MI 48201, USA
E-mail: [email protected]
Received date: October 20, 2015; Accepted date: November 12, 2015; Published date: November 19, 2015
Citation: Ali S, Dubaybo H, Brand RE, Sarkar FH (2015) Differential Expression of Micrornas in Tissues and Plasma Co-exists as a Biomarker for Pancreatic Cancer. J Cancer Sci Ther 7:336-346. doi:10.4172/1948-5956.1000372
Copyright: © 2015 Ali S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Objective: Pancreatic cancer (PC) is a lethal disease with disappointing results from current treatment modalities, suggesting that novel therapeutic strategies are urgently needed. Since microRNAs (miRNAs) are important player in biology, the clinical utility of miRNAs for designing novel therapeutics is an active area of research. The objective of the present study was to examine differentially expressed miRNAs between normal and tumor tissues, and in plasma samples obtained from PC patients, chronic pancreatitis (CP) patients and healthy subjects (HC).
Material and methods: The miRNA expression profiling using formalin-fixed paraffin embedded (FFPE) tissues from normal and tumor specimens was accomplished using miRBase version 19 (LC Sciences, Houston, TX, USA). Quantitative real-time PCR (qRT-PCR) was subsequently performed in individual samples for 7 selected miRNAs. In addition, qRT-PCR was also performed for assessing the expression of 8 selected miRNAs in plasma samples.
Results: A significant difference in the expressions of miR-21, miR-205, miR-155, miR-31, miR-203, miR-214 and miR-129-2 were found in tumor tissue samples. Lower expression of miR-214 was found to be associated with better overall survival. We also observed differential expression of 8 miRNAs in plasma samples of CP and PC patients compared to HC. Interestingly, over expression of miR-21, and miR-31 was noted in both tumor tissues and in the plasma.
Conclusion: We found deregulated expression of miRNAs that could distinguish normal from PC in two different types of samples (tissues and plasma). Interestingly, lower expression of miR-214 was found to be associated with better overall survival. Although not statistically significant, we also observed higher expression of let-7a and lower expression of miR-508 to be associated with overall better survival. We conclude that our study nicely lays the foundation for detailed future investigations for assessing the role of these miRNAs in the pathology of pancreatic cancer.